Last reviewed · How we verify
Cox-2
Cox-2 inhibitors selectively block cyclooxygenase-2 enzyme to reduce prostaglandin production and inflammation.
Cox-2 inhibitors selectively block cyclooxygenase-2 enzyme to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Cox-2 |
|---|---|
| Also known as | ParecoxibNa |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Drug class | Cox-2 selective inhibitor (NSAID) |
| Target | Cyclooxygenase-2 (Cox-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management / Inflammation |
| Phase | FDA-approved |
Mechanism of action
Cox-2 (cyclooxygenase-2) inhibitors are nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the Cox-2 enzyme, which is primarily responsible for producing inflammatory prostaglandins. By blocking Cox-2 while sparing Cox-1, these drugs reduce inflammation and pain with potentially fewer gastrointestinal side effects compared to non-selective NSAIDs. They are used for anti-inflammatory and analgesic purposes in various conditions.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Inflammation
Common side effects
- Gastrointestinal upset
- Cardiovascular events (thrombotic)
- Renal impairment
- Hypertension
Key clinical trials
- Clinical Evaluation of Arthrocentesis, Combination of Platelet-Rich Plasma and Cyclooxygenase Enzyme-2 Inhibitor in Treatment of Temporo-Mandibular Joint Anterior Displacement (PHASE3)
- PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) (PHASE1)
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (PHASE2)
- The COX-2 Gene and the Immune System
- PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease (PHASE1)
- Mechanisms of Action of Acetaminophen (NA)
- Clinical and Laboratory Evaluation of Resveratrol Loaded Nanoparticles in the Treatment of Periodontitis: A Randomized Controlled Clinical Trial (PHASE1)
- Percutaneous Cryoablation of Intercostal Nerves for the Treatment of Rib Fractures (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cox-2 CI brief — competitive landscape report
- Cox-2 updates RSS · CI watch RSS
- First Affiliated Hospital Xi'an Jiaotong University portfolio CI